Recent News

• 07.15.2026 - Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
• 07.14.2026 - Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
• 07.07.2026 - Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
• 06.26.2026 - Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
• 06.18.2026 - Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
• 06.15.2026 - Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
• 06.04.2026 - Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
• 06.03.2026 - Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
• 06.01.2026 - Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
• 05.27.2026 - Axsome Therapeutics to Participate in Upcoming Investor Conferences

Recent Filings

• 07.15.2026 - 8-K Current report
• 07.15.2026 - EX-99.1 EX-99.1
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 144 Report of proposed sale of securities
• 06.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.11.2026 - 144 Report of proposed sale of securities
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities